StockMacro
Company, fund or insider

Help

Menu

Prelude Therapeutics

PRLD on XNAS, Prelude Therapeutics Incorporated

Measures activity, not value. Not investment advice.

Shares sold short (30 Oct 2026)

4.2M

-18% vs the report before

Short interest, % of shares outstanding

5.2%

80.1M shares outstanding (11 Nov 2026)

Days to cover

9.1

short interest / daily volume

Short sale volume share (20 Nov 2026)

60%

1-year median 47%

Sharp changes

13

short interest spike

Window
4.2M shares sold short on 30 Oct 2026, 5.2% of shares outstanding, 9.1 days to cover

FINRA short interest by settlement date (the 15th and the last business day of each month). FINRA publishes each report 7 business days after its settlement date. Dashed: 3-year median.

See the numbers
30 Oct 2026: 4.2M shares sold short, 9.1 days to cover
15 Oct 2026: 5.1M shares sold short, 11.5 days to cover
30 Sep 2026: 4.6M shares sold short, 7.9 days to cover
15 Sep 2026: 3.6M shares sold short, 9.0 days to cover
31 Aug 2026: 3.6M shares sold short, 5.6 days to cover
14 Aug 2026: 3.8M shares sold short, 9.8 days to cover
31 Jul 2026: 3.7M shares sold short, 9.3 days to cover
15 Jul 2026: 3.3M shares sold short, 9.5 days to cover
30 Jun 2026: 2.8M shares sold short, 3.5 days to cover
15 Jun 2026: 1.8M shares sold short, 6.3 days to cover
29 May 2026: 1.7M shares sold short, 5.4 days to cover
15 May 2026: 1.9M shares sold short, 3.5 days to cover
30 Apr 2026: 1.6M shares sold short, 2.7 days to cover
15 Apr 2026: 1.8M shares sold short, 5.2 days to cover
31 Mar 2026: 2.3M shares sold short, 13.8 days to cover
13 Mar 2026: 2.3M shares sold short, 8.1 days to cover
27 Feb 2026: 2.3M shares sold short, 6.2 days to cover
13 Feb 2026: 2.4M shares sold short, 8.9 days to cover
30 Jan 2026: 2.1M shares sold short, 4.8 days to cover
15 Jan 2026: 1.7M shares sold short, 3.1 days to cover
31 Dec 2025: 1.5M shares sold short, 2.6 days to cover
15 Dec 2025: 1.3M shares sold short, 3.3 days to cover
28 Nov 2025: 996K shares sold short, 2.0 days to cover
14 Nov 2025: 1.3M shares sold short, 1.0 days to cover
31 Oct 2025: 567K shares sold short, 2.1 days to cover
15 Oct 2025: 515K shares sold short, 2.4 days to cover
30 Sep 2025: 601K shares sold short, 1.6 days to cover
15 Sep 2025: 538K shares sold short, 4.1 days to cover
29 Aug 2025: 531K shares sold short, 1.8 days to cover
15 Aug 2025: 510K shares sold short, 4.5 days to cover
31 Jul 2025: 595K shares sold short, 4.3 days to cover
15 Jul 2025: 521K shares sold short, 5.0 days to cover
30 Jun 2025: 546K shares sold short, 1.9 days to cover
13 Jun 2025: 841K shares sold short, 4.8 days to cover
30 May 2025: 946K shares sold short, 5.9 days to cover
15 May 2025: 878K shares sold short, 7.9 days to cover
30 Apr 2025: 979K shares sold short, 8.3 days to cover
15 Apr 2025: 2.3M shares sold short, 11.8 days to cover
31 Mar 2025: 2.4M shares sold short, 7.5 days to cover
14 Mar 2025: 2.3M shares sold short, 13.2 days to cover
28 Feb 2025: 2.2M shares sold short, 12.8 days to cover
14 Feb 2025: 3.1M shares sold short, 14.1 days to cover
31 Jan 2025: 3.1M shares sold short, 12.4 days to cover
15 Jan 2025: 3.1M shares sold short, 11.4 days to cover
31 Dec 2024: 3.4M shares sold short, 3.3 days to cover
13 Dec 2024: 3.3M shares sold short, 7.1 days to cover
29 Nov 2024: 3.1M shares sold short, 9.9 days to cover
15 Nov 2024: 2.9M shares sold short, 7.9 days to cover
31 Oct 2024: 2.9M shares sold short, 7.0 days to cover
15 Oct 2024: 2.5M shares sold short, 14.9 days to cover
30 Sep 2024: 2.5M shares sold short, 5.7 days to cover
13 Sep 2024: 3.3M shares sold short, 6.3 days to cover
30 Aug 2024: 2.4M shares sold short, 10.9 days to cover
15 Aug 2024: 1.4M shares sold short, 9.3 days to cover
31 Jul 2024: 771K shares sold short, 4.0 days to cover
15 Jul 2024: 528K shares sold short, 4.3 days to cover
28 Jun 2024: 560K shares sold short, 8.8 days to cover
14 Jun 2024: 567K shares sold short, 14.6 days to cover
31 May 2024: 585K shares sold short, 12.4 days to cover
15 May 2024: 609K shares sold short, 18.3 days to cover

What the numbers say

  • 4.2M shares sold short on 30 Oct 2026, 5.2% of shares outstanding, 9.1 days to cover; -18% on the report before (published by FINRA on 10 Nov 2026).

Every measure from this source

Short interest is a position, reported twice a month. Short sale volume is a different measure: the share of each day's trading on off-exchange venues that was a short sale. Market makers sell short routinely, so 40% to 50% is normal.

Days to cover. 9.1 days in the report of 30 Oct 2026, 1.0 a year earlier.
Short interest, % of shares outstanding. 5.2% in the report of 30 Oct 2026, 2.0% a year earlier.
Daily short sale volume share on off-exchange venues. 60% of the off-exchange volume on 20 Nov 2026 was a short sale; its median of the last 12 months 47%. This is a daily flow, not short interest.

Sharp changes

13 in all loaded history, strongest first

Prelude Therapeutics had 3.4M shares sold short in the 31 Dec 2024 report, 7.6× the same report last year.

Short interest spike, became public on 14 Jan 2025

Same report last year: 447K; its normal report is 626K.

See the evidence
This period
3.4M (the 31 Dec 2024 report)
Normal report (median of 24 earlier)
626K
Typical spread (median absolute deviation)
134K
How far from its usual level
+13.9
Same report last year
447K
History used
1,553 days
2023-12-29: 447K2024-01-12: 451K2024-01-31: 522K2024-02-15: 504K2024-02-29: 619K2024-03-15: 643K2024-03-28: 622K2024-04-15: 604K2024-04-30: 631K2024-05-15: 609K2024-05-31: 585K2024-06-14: 567K2024-06-28: 560K2024-07-15: 528K2024-07-31: 771K2024-08-15: 1.4M2024-08-30: 2.4M2024-09-13: 3.3M2024-09-30: 2.5M2024-10-15: 2.5M2024-10-31: 2.9M2024-11-15: 2.9M2024-11-29: 3.1M2024-12-13: 3.3M2024-12-31: 3.4M
the 31 Dec 2024 report24 earlier reportsnormal: 626K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Prelude Therapeutics had 3.3M shares sold short in the 13 Sep 2024 report, 1.9× the same report last year.

Short interest spike, became public on 25 Sep 2024

Same report last year: 1.7M; its normal report is 626K.

See the evidence
This period
3.3M (the 13 Sep 2024 report)
Normal report (median of 24 earlier)
626K
Typical spread (median absolute deviation)
109K
How far from its usual level
+16.7
Same report last year
1.7M
History used
1,444 days
2023-09-15: 1.7M2023-09-29: 1.9M2023-10-13: 799K2023-10-31: 800K2023-11-15: 804K2023-11-30: 741K2023-12-15: 680K2023-12-29: 447K2024-01-12: 451K2024-01-31: 522K2024-02-15: 504K2024-02-29: 619K2024-03-15: 643K2024-03-28: 622K2024-04-15: 604K2024-04-30: 631K2024-05-15: 609K2024-05-31: 585K2024-06-14: 567K2024-06-28: 560K2024-07-15: 528K2024-07-31: 771K2024-08-15: 1.4M2024-08-30: 2.4M2024-09-13: 3.3M
the 13 Sep 2024 report24 earlier reportsnormal: 626K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Prelude Therapeutics had 3.3M shares sold short in the 13 Dec 2024 report, 4.8× the same report last year.

Short interest spike, became public on 25 Dec 2024

Same report last year: 680K; its normal report is 626K.

See the evidence
This period
3.3M (the 13 Dec 2024 report)
Normal report (median of 24 earlier)
626K
Typical spread (median absolute deviation)
113K
How far from its usual level
+15.7
Same report last year
680K
History used
1,535 days
2023-12-15: 680K2023-12-29: 447K2024-01-12: 451K2024-01-31: 522K2024-02-15: 504K2024-02-29: 619K2024-03-15: 643K2024-03-28: 622K2024-04-15: 604K2024-04-30: 631K2024-05-15: 609K2024-05-31: 585K2024-06-14: 567K2024-06-28: 560K2024-07-15: 528K2024-07-31: 771K2024-08-15: 1.4M2024-08-30: 2.4M2024-09-13: 3.3M2024-09-30: 2.5M2024-10-15: 2.5M2024-10-31: 2.9M2024-11-15: 2.9M2024-11-29: 3.1M2024-12-13: 3.3M
the 13 Dec 2024 report24 earlier reportsnormal: 626K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Prelude Therapeutics had 3.1M shares sold short in the 31 Jan 2025 report, 6.0× the same report last year.

Short interest spike, became public on 12 Feb 2025

Same report last year: 522K; its normal report is 707K.

See the evidence
This period
3.1M (the 31 Jan 2025 report)
Normal report (median of 24 earlier)
707K
Typical spread (median absolute deviation)
194K
How far from its usual level
+8.5
Same report last year
522K
History used
1,584 days
2024-01-31: 522K2024-02-15: 504K2024-02-29: 619K2024-03-15: 643K2024-03-28: 622K2024-04-15: 604K2024-04-30: 631K2024-05-15: 609K2024-05-31: 585K2024-06-14: 567K2024-06-28: 560K2024-07-15: 528K2024-07-31: 771K2024-08-15: 1.4M2024-08-30: 2.4M2024-09-13: 3.3M2024-09-30: 2.5M2024-10-15: 2.5M2024-10-31: 2.9M2024-11-15: 2.9M2024-11-29: 3.1M2024-12-13: 3.3M2024-12-31: 3.4M2025-01-15: 3.1M2025-01-31: 3.1M
the 31 Jan 2025 report24 earlier reportsnormal: 707K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Prelude Therapeutics had 3.1M shares sold short in the 15 Jan 2025 report, 6.9× the same report last year.

Short interest spike, became public on 28 Jan 2025

Same report last year: 451K; its normal report is 637K.

See the evidence
This period
3.1M (the 15 Jan 2025 report)
Normal report (median of 24 earlier)
637K
Typical spread (median absolute deviation)
134K
How far from its usual level
+12.5
Same report last year
451K
History used
1,568 days
2024-01-12: 451K2024-01-31: 522K2024-02-15: 504K2024-02-29: 619K2024-03-15: 643K2024-03-28: 622K2024-04-15: 604K2024-04-30: 631K2024-05-15: 609K2024-05-31: 585K2024-06-14: 567K2024-06-28: 560K2024-07-15: 528K2024-07-31: 771K2024-08-15: 1.4M2024-08-30: 2.4M2024-09-13: 3.3M2024-09-30: 2.5M2024-10-15: 2.5M2024-10-31: 2.9M2024-11-15: 2.9M2024-11-29: 3.1M2024-12-13: 3.3M2024-12-31: 3.4M2025-01-15: 3.1M
the 15 Jan 2025 report24 earlier reportsnormal: 637K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Prelude Therapeutics had 3.1M shares sold short in the 29 Nov 2024 report, 4.1× the same report last year.

Short interest spike, became public on 11 Dec 2024

Same report last year: 741K; its normal report is 626K.

See the evidence
This period
3.1M (the 29 Nov 2024 report)
Normal report (median of 24 earlier)
626K
Typical spread (median absolute deviation)
109K
How far from its usual level
+15.0
Same report last year
741K
History used
1,521 days
2023-11-30: 741K2023-12-15: 680K2023-12-29: 447K2024-01-12: 451K2024-01-31: 522K2024-02-15: 504K2024-02-29: 619K2024-03-15: 643K2024-03-28: 622K2024-04-15: 604K2024-04-30: 631K2024-05-15: 609K2024-05-31: 585K2024-06-14: 567K2024-06-28: 560K2024-07-15: 528K2024-07-31: 771K2024-08-15: 1.4M2024-08-30: 2.4M2024-09-13: 3.3M2024-09-30: 2.5M2024-10-15: 2.5M2024-10-31: 2.9M2024-11-15: 2.9M2024-11-29: 3.1M
the 29 Nov 2024 report24 earlier reportsnormal: 626K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.